Marc Alix Peyrat

Title: Marc Alix Peyrat: Innovator in Selective T Lymphocyte Inhibition

Introduction

Marc Alix Peyrat is a notable inventor based in Sebastien, France. He has made significant contributions to the field of immunology through his innovative research and patenting activities. His work focuses on compounds that selectively inhibit gamma 9 delta 2 T lymphocytes, which are crucial in various therapeutic applications.

Latest Patents

Marc Alix Peyrat holds a patent for "Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes." This invention concerns compounds represented as CH —R —(CH ) —R, where R is selected from a tertiary alcohol, a 1,2-diol, a halohydrine, an epoxide, an alkene, an aldehyde, or an α-hydroxyaldehyde. Additionally, R can be a methylenediphosphonate, a difluoromethylenediphosphonate, or a monofluoromethylenediphosphoneate. The patent also discusses the uses of these compounds as selective inhibitors of Tγ9δ2 lymphocytes, particularly for therapeutic purposes. He has 1 patent to his name.

Career Highlights

Throughout his career, Marc Alix Peyrat has demonstrated a commitment to advancing medical science through his innovative approaches. His research has the potential to impact therapeutic strategies significantly, particularly in the realm of immunotherapy.

Collaborations

Marc has collaborated with notable colleagues, including Christian Belmant and Marc Bonneville. Their combined expertise has contributed to the development of groundbreaking research in the field.

Conclusion

Marc Alix Peyrat is a distinguished inventor whose work in selective T lymphocyte inhibition showcases his dedication to advancing medical science. His innovative compounds hold promise for therapeutic applications, marking him as a key figure in his field.